Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. [artículo]
Por: Manso Sánchez, Luis [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Editor: Annals of oncology: official journal of the European Society for Medical Oncology, 2013Descripción: 24(1):109-16.Recursos en línea: Solicitar documento Resumen: BACKGROUND: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer.Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
---|---|---|---|---|
Artículo | PC1560 (Navegar estantería) | Disponible |
Formato Vancouver:
Awada A, Dirix L, Manso Sánchez L, Xu B, Luu T, Diéras V et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013
Jan;24(1):109-16.
PMID: 22967996
Contiene 43 referencias
BACKGROUND: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer.
No hay comentarios para este ejemplar.